Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-07-02T12:41:34.776Z Has data issue: false hasContentIssue false

EPA-1812 – Alzheimer's Disease Treatment Related Nausea Side Effect

Published online by Cambridge University Press:  15 April 2020

J. Batistela
Affiliation:
Basic Sciences, Albert Einstein Hospital, São Paulo, Brazil
S. Salman
Affiliation:
Geriatrics, Premier Hospital, São Paulo, Brazil
J. Ropero Peláez
Affiliation:
Mathematics Computation and Cognition, Universidade Federal do ABC, Santo andré, Brazil
B. Leon
Affiliation:
Basic Sciences, Albert Einstein Hospital, São Paulo, Brazil
R. Mason
Affiliation:
Gastronomy and Nutrition, São Camilo, São Paulo, Brazil
S. Taniguchi
Affiliation:
Basic Sciences, Albert Einstein Hospital, São Paulo, Brazil

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Nausea/vomiting and other gastrointestinal system disorders may cause severe nutritional complication in elderly neurologic patients.

Objectives

To identify possible gastrointestinal side effects in patients receiving Alzheimer's disease treatment.

Methods

This research included 45 geriatric patients enrolled in a private long-term care institution with mean age of 88.38 ± 0.84 years old, mean weight of en 60.28 ± 2.00 kg with Alzheimer's disease.

Results

Drugs administered to patients with Alzheime's disease were: donepezil 0.16 mg/kg/day, administered to 53.33% (24) of patients ; rivastigmine patch 9.50 mg/day given to15.56%(7) of patients and galantamine 0.40 mg/kg/day given to 4.44% (2) of patients.

26.67% (12) of subjects did not received any specific drug for Alzheimer's disease.

Nausea and vomiting were observed in 20,83% (5) patients who received donepezil, in 85.71% (6) from rivastigmine group and in 2 patients treated with galantamine.

Appetite loss was identified in 20,83% of patients receiving donepezil.

Conclusion

The increase of cholinergic activity induced by donepezil, rivastigmine and galantamine intensify cholinergic neurons inputs from chemoreceptor trigger zone, solitary tract nucleus and cerebellum to medullary emetic centre and thus may lead to emese stimulation in these patients.

Regarding the possibility of nausea/vomiting and appetite loss in patients receiving Alzheimer's disease cholinergic drugs, a more easily digestible meal should be considered for these patients.

Type
P15 - Geriatric Psychiatry
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.